Literature DB >> 11778806

Pterygium in Australia: a cost of illness study.

J Wlodarczyk1, P Whyte, P Cockrum, H Taylor.   

Abstract

PURPOSE: The aim of this report was to describe the number of Australians affected by pterygium in recent years, treatment options, number of treatment encounters and costs of treatment.
METHOD: A review of published literature was conducted to identify the prevalence of pterygium in Australian populations. Costs of primary care were based on national general practitioner (GP) survey data. Costs of surgical intervention were based on Health Insurance Commission claims data and Australian Institute of Health and Welfare National Hospital Morbidity Data.
RESULTS: Pterygium occurs in 1.1% of Australians. It is more prevalent in populations with higher exposure to ultraviolet radiation, and older men (occurring in 12% of males over 60 years). The estimated annual number of GP contacts was 58,900. Forty per cent of primary care contacts for pterygium were referred to an ophthalmologist and topical medication was prescribed by GPs in 32% of contacts. The estimated annual cost of GP visits, specialist visits and topical medication was AUD$3.2 m. There were 6997 claims for pterygium removal in 1999/2000 with 3192 conjunctival autografts. Rates of pterygium removal were highest in Queensland with 56 per 100,000 population. The annual costs of surgical intervention were estimated at AUD$4.8 m.
CONCLUSIONS: The direct medical costs of pterygium in Australia are AUD$8.3 m annually. This is likely to be an underestimate of total cost because indirect costs such as loss of work time could not be measured. More data are needed on the long-term benefits of pterygium intervention.

Entities:  

Mesh:

Year:  2001        PMID: 11778806     DOI: 10.1046/j.1442-9071.2001.d01-21.x

Source DB:  PubMed          Journal:  Clin Exp Ophthalmol        ISSN: 1442-6404            Impact factor:   4.207


  5 in total

1.  The risk of pterygium in salt workers.

Authors:  Murli L Mathur; Kripa Ram Haldiya; Raman Sachdev; Habibulla N Saiyed
Journal:  Int Ophthalmol       Date:  2006-06-16       Impact factor: 2.031

Review 2.  Cost-of-illness studies : a review of current methods.

Authors:  Ebere Akobundu; Jing Ju; Lisa Blatt; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

3.  Peroxiredoxin I and II in human eyes: cellular distribution and association with pterygium and DNA damage.

Authors:  Sonja Klebe; Thomas Callahan; John H T Power
Journal:  J Histochem Cytochem       Date:  2013-10-23       Impact factor: 2.479

4.  Genetic and environmental factors in conjunctival UV autofluorescence.

Authors:  Seyhan Yazar; Gabriel Cuellar-Partida; Charlotte M McKnight; Piriya Quach-Thanissorn; Jenny A Mountain; Minas T Coroneo; Craig E Pennell; Alex W Hewitt; Stuart MacGregor; David A Mackey
Journal:  JAMA Ophthalmol       Date:  2015-04       Impact factor: 7.389

5.  Pterygium and Ocular Surface Squamous Neoplasia: Optical Biopsy Using a Novel Autofluorescence Multispectral Imaging Technique.

Authors:  Abbas Habibalahi; Alexandra Allende; Jesse Michael; Ayad G Anwer; Jared Campbell; Saabah B Mahbub; Chandra Bala; Minas T Coroneo; Ewa M Goldys
Journal:  Cancers (Basel)       Date:  2022-03-21       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.